Always a bridesmaid, never a bride: Committing to flu neuraminidase as a vaccine target.
Always a bridesmaid, never a bride: Committing to flu neuraminidase as a vaccine target.
复制标题
永远是伴娘，而不是新娘：致力于将流感神经氨酸酶作为疫苗目标。
DOI：
10.1016/j.ymthe.2023.04.014
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Coughlan,Lynda
中科院分区：
文献类型：
--
作者：
Schneider,Cosette;Coughlan,Lynda
甲型流感病毒由于其在季节性流行病中的作用以及从动物宿主中出现新型病毒的可能性而构成持续的威胁。 1 人们正在大力开发能够针对多种流感病毒抗原提供保护的疫苗，以及针对抗原不同的季节性和/或大流行病毒提供广泛保护的通用疫苗。为了实现长效和交叉保护性免疫，人们认为可能需要在异源初免：加强方案中组合不同的疫苗平台。 2在本期《分子治疗》中，Werninghaus 及其同事评估了一种基于质粒 DNA 的新型疫苗接种方法的潜力，其中编码的抗原通过与识别 MHC II 的单链可变片段 (scFv) 融合而靶向抗原呈递细胞 (APC)。 3 基于作者之前成功设计出针对流感病毒血凝素 (HA) 的类似疫苗，4 在当前的研究中，作者选择流感病毒神经氨酸酶 (NA) 作为目标抗原。通过一系列小鼠体内免疫原性和功效实验，他们证明他们的疫苗可以引发 NA 特异性体液和细胞免疫反应，并提供针对同源流感病毒攻击的保护。因此，这项研究扩展了我们目前在创新 DNA 疫苗平台背景下对基于 NA 的免疫的理解，并进一步巩固了 NA 作为流感疫苗开发领先目标的地位。
Influenza A viruses pose an ongoing threat due to their role in seasonal epidemics and the potential for the emergence of novel viruses from the animal reservoir. 1 Extensive efforts are being made to develop vaccines that elicit protection against multiple influenza virus antigens, as well as universal vaccines that confer broad protection against antigenically distinct seasonal and/or pandemic viruses. In order to achieve long-lived and cross-protective immunity, it is considered that combining distinct vaccine platforms in heterologous prime: boost regimens may be required. 2In this issue of Molecular Therapy, Werninghaus and colleagues evaluate the potential of a novel plasmid DNA-based vaccination approach in which the encoded antigen is targeted to antigen-presenting cells (APCs) by fusion to a single chain variable fragment (scFv) recognizing MHC II. 3 Building upon the authors’ prior success in engineering a similar vaccine against influenza virus hemagglutinin (HA), 4 in the current study, the authors selected influenza virus neuraminidase (NA) as their target antigen. Through a series of in vivo immunogenicity and efficacy experiments in mice, they demonstrated that their vaccine could elicit NA-specific humoral and cellular immune responses and confer protection against homologous influenza virus challenge. As such, this study expands our current understanding of NA-based immunity in the context of an innovative DNA vaccine platform, and it further solidifies NA as a leading target in influenza vaccine development.